SuperworthNeogen profit margin NEOG
Gross, operating and net profit as a share of revenue over the last twelve months, from 2011.
- Net margin, 12 months
- −6.3%
- Operating margin, 12 months
- −0.8%
- Peer median
- 10.6%
Over the twelve months to Aug 31, 2026, Neogen kept −6.3% of its revenue as net profit, with an operating margin of −0.8% and a gross margin of 47.4%.
Five years earlier its net margin was 12.7%.
The median for 9 diagnostics and research stocks of a similar size is 10.6%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2026 | −0.9% | −2.5% | 46.9% |
| FY2025 | n/a | n/a | 47.1% |
| FY2024 | −1.0% | 6.3% | 50.2% |
| FY2023 | −2.8% | 4.6% | 49.4% |
| FY2022 | 9.2% | 11.1% | 46.1% |
| FY2021 | 13.0% | 15.8% | 45.9% |
| FY2020 | 14.2% | 16.1% | 46.9% |
| FY2019 | 14.5% | 16.4% | 46.3% |
| FY2018 | 15.9% | 17.6% | 46.8% |
| FY2017 | 12.1% | 18.0% | 47.6% |
| FY2016 | 11.4% | 17.6% | 47.6% |
| FY2015 | 11.8% | 18.8% | 49.3% |
| FY2014 | 11.4% | 17.5% | 49.6% |
| FY2013 | 13.1% | 19.6% | 52.8% |
| FY2012 | 12.2% | 18.3% | 50.2% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q1 FY27 | −6.3% | n/a | −0.8% | |
| Q4 FY26 | −0.9% | n/a | −2.5% | |
| Q3 FY26 | −69.9% | −16.4 pts | −73.1% | |
| Q2 FY26 | −68.5% | −16.3 pts | −71.3% | |
| Q1 FY26 | n/a | n/a | n/a | |
| Q4 FY25 | n/a | n/a | n/a | |
| Q3 FY25 | −53.6% | −53.7 pts | −48.2% | |
| Q2 FY25 | −52.1% | −53.4 pts | −47.1% | |
| Q1 FY25 | −2.6% | +0.3 pts | 4.6% | |
| Q4 FY24 | −1.0% | +1.8 pts | 6.3% | |
| Q3 FY24 | 0.2% | +2.0 pts | 7.4% | |
| Q2 FY24 | 1.3% | +3.9 pts | 7.9% |
Against its peers
Companies in Medical - Diagnostics & Research nearest Neogen's size, closest first, today.
| Company | Profit margin |
|---|---|
| NEOGNeogen | −6.3% |
| CDNACareDx | 24.2% |
| VCYTVeracyte | 20.4% |
| BLLNBillionToOne | 9.5% |
| LNTHLantheus | 17.7% |
| CAICaris Life Sciences | 10.6% |
| BIOBio-Rad Laboratories | 8.6% |
| NRCNRC Health | 4.2% |
| RVTYRevvity | 8.2% |
| MEDPMedpace | 17.7% |
| Peer median | 10.6% |
Where Neogen ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Neogen
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.